Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;29(4):2966-77.
doi: 10.1007/s12032-012-0168-1.

Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients

Sergiusz Markowicz  1 , Zbigniew I Nowecki, Piotr Rutkowski, Andrzej W Lipkowski, Marzena Biernacka, Anna Jakubowska-Mucka, Tomasz Switaj, Aleksandra Misicka, Henryk Skurzak, Hanna Polowniak-Pracka, Jan Walewski
Affiliations

Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients

Sergiusz Markowicz et al. Med Oncol. 2012 Dec.

Abstract

Dendritic cells may be successfully used to induce in vivo-specific anti-tumor responses when combined with the appropriate antigen in the appropriate context. The purpose of this study was to evaluate efficacy of peptide-loaded DC vaccine in high-risk stage III melanoma patients after lymph node dissection (LND). HLA-A2+, -A1+, or -A3+ melanoma patients (N=22), stage III, N1b-N3, received 5–16 (median: 11) DC vaccines loaded with MHC class-I-restricted melanoma peptides respective to the patient’s haplotype, and with autologous tumor lysate, if available. Vaccinated patients were matched to unvaccinated stage III controls (22 of 869) by sex, number of metastatic lymph nodes, extracapsular involvement, LND type, Breslow stage, and ulceration. Vaccination elicited cutaneous delayed-type hypersensitivity (DTH) or/and IFN-γ-producing CD8+ cell response to melanoma peptides in 15 of 22 patients. Three-year overall survival (OS) rate was 68.2% in the vaccinated group versus 25.7% in the control group, P value accounting for matching: 0.0290. In a Cox regression model, hazard ratio (HR) for death of vaccinated patients was 0.31 [95% confidence interval (CI): 0.10–0.94]. The corresponding values for 3-year disease-free survival rate were 40.9 versus 14.5%, P=0.1083; HR of recurrence for vaccinated, 0.46 (95% CI: 0.18–1.22). There was no grade>1 toxicity. The DC/peptide vaccine was well tolerated and elicited immune responses to melanoma antigens. Vaccinated patients had significantly longer OS after LND than the matched controls, but a significant improvement in the primary endpoint DFS was not achieved.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Immunol. 1997 Feb 15;158(4):1796-802 - PubMed
    1. Melanoma Res. 2007 Oct;17(5):316-22 - PubMed
    1. J Clin Invest. 1990 Mar;85(3):955-61 - PubMed
    1. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
    1. J Clin Oncol. 2010 Mar 1;28(7):1196-202 - PubMed

LinkOut - more resources

-